Exelixis Inc

21 de out. de 2026, 19:26 UTC

Exelixis Inc shares are trading slightly higher, supported by positive momentum in the broader biotechnology sector, despite an earlier pullback from a session high.

20 de out. de 2026, 20:08 UTC

Exelixis Inc shares advanced, closing significantly higher and reaching a notable peak, remaining well above its 20-day moving average.

19 de out. de 2026, 20:07 UTC

Citizens maintains Market Outperform rating on Exelixis and raises price target to $65, contributing to a modest gain in the stock.

16 de out. de 2026, 19:16 UTC

Exelixis Inc shares fell significantly from an early high, remaining above the 20-day moving average despite today's notable decline.

15 de out. de 2026, 20:07 UTC

Exelixis Inc shares advanced, continuing a trend of gains since Wednesday's close, remaining significantly above its 20-day moving average despite an earlier pullback.

14 de out. de 2026, 19:16 UTC

Exelixis Inc shares are advancing, reaching a notable peak in early afternoon trading and positioned well above its 20-day moving average.

13 de out. de 2026, 20:08 UTC

Exelixis Inc shares are modestly lower, retracing from an early gain, amid a broader market decline.

12 de out. de 2026, 21:02 UTC

Exelixis Inc shares declined in after-market trading, continuing lower since Monday's close and diverging from a recent trend of higher daily closes.

9 de out. de 2026, 20:06 UTC

RBC Capital raised its price target on Exelixis Inc to $51 while maintaining a Sector Perform rating, coinciding with the stock's positive performance.

8 de out. de 2026, 20:07 UTC

Exelixis Inc's shares advanced, supported by broader market strength, maintaining an upward trajectory despite an earlier pullback from a session high.

7 de out. de 2026, 19:45 UTC

Exelixis Inc shares are trading higher as Truist Securities raises the price target to $54.00 from $52.00 while maintaining a Hold rating.

6 de out. de 2026, 21:01 UTC

Exelixis Inc is trading modestly lower in after-market hours, positioned around the midpoint of its one-month trading range.

5 de out. de 2026, 21:10 UTC

Exelixis Inc. is advancing in after-market trading, closing at its highest point of the day after three consecutive sessions of gains.

2 de out. de 2026, 20:00 UTC

Exelixis Inc shares are advancing, reaching a peak cumulative return and remaining well above their 20-day moving average during Friday's market session.

1 de out. de 2026, 20:07 UTC

Exelixis Inc's shares fell modestly, reflecting routine performance amid broader market conditions, and are currently near the low end of their daily range.

30 de set. de 2026, 23:20 UTC

Exelixis Inc shares are higher in after-market trading, continuing a five-day gain, supported by strong Q2 GDP growth despite mixed inflation and consumer spending signals.

29 de set. de 2026, 20:31 UTC

Exelixis Inc saw a significant decline in after-market trading, continuing a downward trend since Tuesday's close following earlier gains.

28 de set. de 2026, 19:16 UTC

Exelixis Inc is trading modestly higher, currently 2.25% above its 20-day moving average, reflecting routine activity for this time of day.

25 de set. de 2026, 23:20 UTC

Exelixis Inc is lower in after-market trading, retracing from an early gain and reflecting a decline since Friday's close.

24 de set. de 2026, 20:01 UTC

Exelixis Inc is advancing, peaking in mid-afternoon while remaining above its 20-day moving average and near the upper end of its one-month range.

23 de set. de 2026, 20:07 UTC

Exelixis Inc shares fell significantly on Wednesday, having briefly spiked earlier in the session, reflecting a lack of momentum in either direction.

22 de set. de 2026, 20:06 UTC

Exelixis Inc is gaining today, building on Monday's momentum, with the stock remaining above its 20-day moving average and near its one-month range's upper end.

21 de set. de 2026, 23:25 UTC

Exelixis Inc is trading modestly lower in after-market hours, continuing a decline seen over the past three sessions after reaching a session high.

18 de set. de 2026, 20:06 UTC

Exelixis Inc's shares fell sharply after reaching a notable peak earlier in the session, while remaining above the 20-day moving average.

16 de set. de 2026, 20:07 UTC

Exelixis Inc shares fell sharply, retracing from an early peak in cumulative return amid unusually high market volume on Wednesday.

15 de set. de 2026, 20:07 UTC

Exelixis Inc. shares are higher as the company expands CABOMETYX in renal cell carcinoma and neuroendocrine tumors, reflecting investor confidence amid broader market concerns.

14 de set. de 2026, 20:07 UTC

Exelixis shares are rising after BMO indicated the FDA's PDUFA date extension for Zanzalintinib is procedural, maintaining a $55 price target.

11 de set. de 2026, 20:01 UTC

Exelixis shares are lower as the FDA extends the review period for zanzalintinib by three months, now set for March 3, 2027.

10 de set. de 2026, 20:07 UTC

Exelixis Inc shares are lower amid market reaction to the European Central Bank's interest rate hike. The stock briefly recovered earlier in the session.

9 de set. de 2026, 20:07 UTC

Exelixis announced a $2 million milestone payment to Adagene for preclinical progress on the XB404 program, boosting shares in Wednesday's session.